Welcome to our dedicated page for Sage Therapeutics SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sage Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sage Therapeutics's regulatory disclosures and financial reporting.
Sage Therapeutics (SAGE) reported insider trading activity through a Form 4 filing for Chief Scientific Officer and Interim Head of R&D Michael C. Quirk. On June 24, 2025, Quirk disposed of 113 shares at a price of $9.22 per share through a tax withholding transaction (Code F).
The transaction was related to the vesting of 338 time-based restricted stock units (RSUs) that were originally granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan. The RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments.
Following the reported transaction, Quirk directly owns 30,461 shares of Sage Therapeutics common stock. The Form 4 was filed on behalf of Quirk by attorney-in-fact Brandon Marsh on June 26, 2025.
Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics (SAGE), reported a Form 4 filing on June 28, 2025, detailing changes in beneficial ownership.
Key transaction details:
- On June 24, 2025, Shiferman had 79 shares withheld for tax purposes at a price of $9.22 per share
- The withholding was related to the vesting of 234 time-based restricted stock units (RSUs) granted on October 28, 2021
- These RSUs vest on a schedule of 25% initial vesting on September 24, 2022, followed by twelve equal quarterly installments
- Following the transaction, Shiferman directly owns 30,950 shares of common stock
The transaction was executed under the company's 2014 Stock Option and Incentive Plan, with Brandon Marsh signing as attorney-in-fact for Shiferman on June 26, 2025.